医疗健康领域投融资日报（6月5日）：科伦博泰获得2.5亿美元战略投资

Summary of Key Points Core Viewpoint - The report highlights a total of 28 financing events disclosed on June 5, 2025, involving 16 domestic companies and 12 foreign companies, with a total financing amount of approximately 12.38 billion RMB. The healthcare sector leads in the number of events, while the automotive sector leads in financing amount. Group 1: Domestic Healthcare Sector - The domestic healthcare sector saw 4 companies receiving funding, totaling approximately 1.92 billion RMB [1] - Kelun-Biotech received a strategic investment of 250 million USD, ranking in the top 10% of all strategic investments this year [1] - Qiyu Biotech completed a C round financing of several hundred million RMB, with the investor being Yifeng Capital [1] - Ruizhou Biotech secured A+ round financing of several tens of millions RMB, ranking in the top 50% of all A+ round financings this year [1] - Sipure completed an angel round financing of 200 million RMB, ranking in the top 1% of all angel round financings this year [1] Group 2: Foreign Healthcare Sector - The foreign healthcare sector reported 2 companies being acquired and 1 company receiving funding, totaling approximately 410 million RMB [2] - Focal Medical was acquired by Continuity Biosciences, a US-based biopharmaceutical service provider [2] - Biocrates Life Sciences was acquired by Bruker, an Australian analytical reagent kit developer [2] - Holoeyes completed B+ round financing of 1.6 million USD, focusing on VR organ model technology [2]